Fate Therapeutics advances CAR T-cell therapy pipeline for autoimmune diseases and cancer.

Fate Therapeutics presented its corporate pipeline progress focusing on off-the-shelf cell therapy development with plans to commence Phase 2 studies. The advancement of novel CAR T-cell therapies represents potential clinical and commercial progress for the cell therapy company.